This randomized phase II trial studies how well nivolumab with or without ipilimumab works in
treating patients with gastrointestinal stromal tumor that has spread to other places in the
body or cannot be removed by surgery. Monoclonal antibodies, such as nivolumab and
ipilimumab, interfere with the ability of tumor cells to grow and spread.